Literature DB >> 8019563

Mutation analysis of 19 North American mucopolysaccharidosis type I patients: identification of two additional frequent mutations.

L A Clarke1, P V Nelson, C L Warrington, C P Morris, J J Hopwood, H S Scott.   

Abstract

Mucopolysaccharidosis type I (MPS I) is an autosomal recessive genetic disorder caused by deficiency of the lysosomal glycosidase alpha-L-iduronidase. Patients with this disorder present with varied clinical phenotypes ranging from early severe onset of disease and death in early childhood to mild manifestations compatible with adult life. An understanding of the molecular basis of iduronidase deficiency and its correlation to clinical phenotype will improve prognostic prediction at diagnosis, aid in genetic counselling of families, and provide a framework to more accurately assess experimental treatment protocols. We have used the approach of single-strand conformational polymorphism analysis and direct sequencing of the alpha-L-iduronidase gene in an attempt to define the molecular basis of iduronidase deficiency in affected individuals. An initial series of 19 patients representing 35 independently segregating mutant alleles were studied. In addition to five previously identified mutations (W402X, Q70X, E274X, H82P, and P533R) two novel mutations (A75T and 474-2a-->g) were found. These seven mutations account for 71% of the mutant alleles and 53% of the genotypes in this group of patients. Analysis of a larger independently ascertained group of 103 MPS I patients, mainly of Northern European origin, revealed that together the two novel mutations account for 7% of mutant alleles and are associated with severe clinical phenotypes. These mutations are the most frequent MPS I mutations detected so far after W402X and Q70X. With the definition of these two mutations, a clear picture of the molecular heterogeneity of MPS I is emerging.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8019563     DOI: 10.1002/humu.1380030316

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

1.  Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres.

Authors:  A Vellodi; E P Young; A Cooper; J E Wraith; B Winchester; C Meaney; U Ramaswami; A Will
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

2.  Enzyme replacement in a canine model of Hurler syndrome.

Authors:  R M Shull; E D Kakkis; M F McEntee; S A Kania; A J Jonas; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

3.  Structural study on mutant alpha-L-iduronidases: insight into mucopolysaccharidosis type I.

Authors:  Kanako Sugawara; Seiji Saito; Kazuki Ohno; Torayuki Okuyama; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2008-03-14       Impact factor: 3.172

4.  Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the α-L-iduronidase gene in Hurler-Scheie syndrome.

Authors:  Alia Ahmed; Chester B Whitley; Renee Cooksley; Kyle Rudser; Stephanie Cagle; Nadia Ali; Kathleen Delaney; Brianna Yund; Elsa Shapiro
Journal:  Mol Genet Metab       Date:  2013-12-12       Impact factor: 4.797

5.  Molecular genetic defect underlying alpha-L-iduronidase pseudodeficiency.

Authors:  E L Aronovich; D Pan; C B Whitley
Journal:  Am J Hum Genet       Date:  1996-01       Impact factor: 11.025

6.  Three novel α-L-iduronidase mutations in 10 unrelated Chinese mucopolysaccharidosis type I families.

Authors:  Luning Sun; Chunyi Li; Xiaoyu Song; Ningning Zheng; Haipeng Zhang; Guizhang Dong
Journal:  Genet Mol Biol       Date:  2011-04-01       Impact factor: 1.771

7.  Novel splice site IDUA gene mutation in Tunisian pedigrees with hurler syndrome.

Authors:  Latifa Chkioua; Hela Boudabous; Ibtissem Jaballi; Oussama Grissa; Hadhami Ben Turkia; Neji Tebib; Sandrine Laradi
Journal:  Diagn Pathol       Date:  2018-05-29       Impact factor: 2.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.